B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
At week 28, reduced disease activity was observed in patients with SLE receiving ianalumab plus standard therapies compared with those receiving standard therapies alone, with sustained benefits with further treatment until 1 year, which was well tolerated.
Authors
- Eduardo Mysler (ORCID: https://orcid.org/0000-0002-8993-0313)
- B. P. Magallares López
- Lie Dai (ORCID: https://orcid.org/0000-0001-6596-8889)
- Carol Lau (ORCID: https://orcid.org/0000-0002-9240-092X)
- Tünde Tarr
- Nan Shen (ORCID: https://orcid.org/0000-0002-5875-4417)
- Stephanie Finzel (ORCID: https://orcid.org/0000-0002-7625-9612)
- Pongthorn Narongroeknawin (ORCID: https://orcid.org/0000-0001-8202-6746)
- А. В. Гордиенко (ORCID: https://orcid.org/0000-0002-6901-6436)
- Rafał Wojciechowski (ORCID: https://orcid.org/0000-0002-4055-6519)
- Yi‐Hsing Chen (ORCID: https://orcid.org/0000-0002-2682-939X)
- Shin‐Seok Lee (ORCID: https://orcid.org/0000-0001-6810-7355)
- Stephen J. Oliver (ORCID: https://orcid.org/0000-0002-8542-5926)
- Bernadette Rojkovich (ORCID: https://orcid.org/0000-0002-9370-6939)
- Yuko Kaneko (ORCID: https://orcid.org/0000-0003-2646-5765)
- C. Sips
- Stanislav Ignatenko
- Josefina Cortés-Hernández
- Alexandre Avraméas (ORCID: https://orcid.org/0000-0003-4094-5829)
- Hana Ciferská (ORCID: https://orcid.org/0000-0002-8928-8543)
- Katarzyna Romanowska‐Próchnicka (ORCID: https://orcid.org/0000-0003-1326-2600)
- Sanjiv Ghanshani
- Еlena A. Vishneva (ORCID: https://orcid.org/0000-0001-7398-0562)
- Ajchara Koolvisoot (ORCID: https://orcid.org/0000-0002-9852-4325)
- Masanari Kodera
- Nancy Agmon‐Levin (ORCID: https://orcid.org/0000-0001-9514-3677)
- Lingyun Sun (ORCID: https://orcid.org/0000-0002-5498-4709)
- Piotr Leszczyński (ORCID: https://orcid.org/0000-0003-2174-8811)
- Masato Okada
- Hiroshi Kaneko (ORCID: https://orcid.org/0000-0002-2998-3544)
- J.-F. Viallard
- Eugeny Zotkin
- Joung-Liang Lan
- Alberta Hoi
Institutions
- Semmelweis University (HU)
- Poznan University of Medical Sciences (PL)
- Novartis (Switzerland) (CH)
- University of Debrecen (HU)
- Siriraj Hospital (TH)
- Sun Yat-sen University (CN)
- China Medical University (TW)
- Keio University (JP)
- Charles University (CZ)
- Mahidol University (TH)
- Medical University of Warsaw (PL)
- Sheba Medical Center (IL)
- Renji Hospital (CN)
- University Medical Center Freiburg (DE)
- S. M. Kirov Military Medical Academy (RU)
- Hospital de Sant Pau (ES)
- St. Luke's International Hospital (JP)
- Phramongkutklao Hospital (TH)
- Novartis (India) (IN)
- Taichung Veterans General Hospital (TW)
- Chonnam National University Hospital (KR)
- Institute of Rheumatology (CZ)
- National Center for Global Health and Medicine (JP)
- Sun Yat-sen Memorial Hospital (CN)
- University of Bydgoszcz (PL)
- Chung Shan Medical University Hospital (TW)
- Nanjing Drum Tower Hospital (CN)
- Novartis (United States) (US)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Monash Health (AU)
- Association of Rheumatologists of Russia (RU)
- China Medical University Hospital (TW)
- Vall d'Hebron Hospital Universitari (ES)
- Japan Community Healthcare Organization (JP)
- Ural Institute of Cardiology (RU)
- Chukyo Hospital (JP)
- Monash University (AU)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.ard.2025.11.015
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Novartis Pharma